Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density

2012 ◽  
Vol 28 (1) ◽  
pp. 196-205 ◽  
Author(s):  
Christian Muschitz ◽  
Roland Kocijan ◽  
Astrid Fahrleitner-Pammer ◽  
Solveig Lung ◽  
Heinrich Resch
Keyword(s):  
Bone Mineral Density ◽  
Bone Mineral ◽  
Treatment Result ◽  
Mineral Density ◽  
Teriparatide Treatment

scholarly journals A Fracture Does Not Adversely Affect Bone Mineral Density Responses after Teriparatide Treatment

2011 ◽  
Vol 470 (3) ◽  
pp. 927-936 ◽  
Author(s):  
Aasis Unnanuntana ◽  
Quang V. Ton ◽  
John P. Kleimeyer ◽  
Joseph T. Nguyen ◽  
Joseph M. Lane
Keyword(s):  
Bone Mineral Density ◽  
Bone Mineral ◽  
Mineral Density ◽  
Teriparatide Treatment

scholarly journals Comparison of efficacy and safety of teriparatide and hyaluronic acid - calcitonin combination treatments in Chinese osteoporotic patients with risk of bone fracture: A preliminary investigation

2020 ◽  
Vol 19 (1) ◽  
pp. 183-188
Author(s):  
Changju Hou
Keyword(s):  
Bone Mineral Density ◽  
Alkaline Phosphatase ◽  
Hyaluronic Acid ◽  
Bone Mineral ◽  
Preliminary Investigation ◽  
Serum Osteocalcin ◽  
Efficacy And Safety ◽  
Mineral Density ◽  
Bone Specific Alkaline Phosphatase ◽  
Teriparatide Treatment

Purpose: To evaluate the efficacy and safety of teriparatide and hyaluronic-calcitonin combination treatment in Chinese osteoporotic patients with risk of bone fracture.Methods: Osteoporotic patients aged 30 to 80 years, with at least one vertebral fracture and immediate risk of new vertebral fractures, were recruited from Hangzhou First People's Hospital. They were randomly assigned to two groups (50/group) treated with either teriparatide (20 μg/day) or hyaluronic acid + calcitonin (1:1 ratio, 200 IU daily) for 12 months. The patients were followed up every 3 months. Bone mineral density (BMD) was evaluated using x-ray absorptiometry. The proportion of patients with new fractures was recorded. Changes in serum osteocalcin and serum bone alkaline phosphatase (BSAP) from baseline to endpoint were also measured.Results: Treatment with teriparatide at a dose of 20 μg/day resulted in a significant reduction in the proportion of patients with new fractures (p < 0.05), when compared to patients treated with a combination of hyaluronic acid + calcitonin (200 IU daily). Teriparatide treatment for 12 months resulted in significant increase in lumbar BMD. Significant increases in spine BMD were evident after 3 months of treatment. There were significantly greater increases in serum osteocalcin and BSAP levels in teriparatide-treated patients than in those given hyaluronic acid + calcitonin. The most common treatment adverse event reported by both sexes was dizziness.Conclusion: These results demonstrate that teriparatide is efficacious and well tolerated in Chinese men and post-menopausal women with osteoporosis, when compared to the combination of hyaluronic acid and calcitonin. The efficacy of teriparatide is not associated with gender differences. Keyword: Teriparatide, Calcitonin, Hyaluronic acid, Bone-specific alkaline phosphatase, Postmenopausal, Bone mineral density

scholarly journals Assessing the Effects of Teriparatide Treatment on Bone Mineral Density, Bone Microarchitecture, and Bone Strength

2014 ◽  
Vol 96 (11) ◽  
pp. e90-1-9 ◽  
Author(s):  
Michael Kleerekoper ◽  
Susan L Greenspan ◽  
E. Michael Lewiecki ◽  
Paul D Miller ◽  
David L Kendler ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Bone Strength ◽  
Bone Mineral ◽  
Bone Microarchitecture ◽  
Mineral Density ◽  
Teriparatide Treatment

Vertebral Fracture Risk Is Reduced for Women Who Lose Femoral Neck Bone Mineral Density During Teriparatide Treatment

2008 ◽  
Vol 11 (3) ◽  
pp. 465 ◽  
Author(s):  
Nelson B. Watts ◽  
Paul D. Miller ◽  
Robert Marcus ◽  
Peiqi Chen ◽  
Jody Arsenault ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Vertebral Fracture ◽  
Femoral Neck ◽  
Fracture Risk ◽  
Bone Mineral ◽  
Mineral Density ◽  
Teriparatide Treatment ◽  
Vertebral Fracture Risk

scholarly journals Effects of Previous Antiresorptive Therapy on the Bone Mineral Density Response to Two Years of Teriparatide Treatment in Postmenopausal Women with Osteoporosis

2008 ◽  
Vol 93 (3) ◽  
pp. 852-860 ◽  
Author(s):  
Steven Boonen ◽  
Fernando Marin ◽  
Barbara Obermayer-Pietsch ◽  
Maria E. Simões ◽  
Clare Barker ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Lumbar Spine ◽  
Bone Formation ◽  
Postmenopausal Women ◽  
Bone Mineral ◽  
Antiresorptive Therapy ◽  
Mineral Density ◽  
Teriparatide Treatment ◽  
Bone Formation Markers ◽  
Hip Bmd

Abstract Introduction: EUROFORS was a 2-yr prospective, randomized trial of postmenopausal women with established osteoporosis, designed to investigate various sequential treatments after teriparatide 20 μg/d for 1 yr. The present secondary analysis examined the effects of 2 yr of open-label teriparatide in women previously treated with antiresorptive drugs for at least 1 yr. Methods: A subgroup of 245 women with osteoporosis who had 2 yr of teriparatide treatment were stratified by previous predominant antiresorptive treatment into four groups: alendronate (n = 107), risedronate (n = 59), etidronate (n = 30), and non-bisphosphonate (n = 49). Bone mineral density (BMD) at the lumbar spine and hip was determined after 6, 12, 18, and 24 months, and bone formation markers were measured after 1 and 6 months. Results: Significant increases in bone formation markers occurred in all groups after 1 month of teriparatide treatment. Lumbar spine BMD increased at all visits, whereas a transient decrease in hip BMD, which was subsequently reversed, was observed in all groups. BMD responses were similar in all previous antiresorptive groups. Previous etidronate users showed a higher increase at the spine but not at the hip BMD. Duration of previous antiresorptive therapy and lag time between stopping previous therapy and starting teriparatide did not affect the BMD response at any skeletal site. Treatment-emergent adverse events were similar to those reported in treatment-naive postmenopausal women with osteoporosis treated with teriparatide. Conclusions: Teriparatide induces positive effects on BMD and markers of bone formation in postmenopausal women with established osteoporosis, regardless of previous long-term exposure to antiresorptive therapies.

AB0905 Osteocalcin Levels Can Predict Significant Increases in Bone Mineral Density After Teriparatide Treatment

2015 ◽  
Vol 74 (Suppl 2) ◽  
pp. 1203.1-1203
Author(s):  
R. Fonseca ◽  
D. Gonçalves ◽  
R. Vieira ◽  
J. Abelha-Aleixo ◽  
G. Terroso ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Bone Mineral ◽  
Mineral Density ◽  
Teriparatide Treatment

Determinants associated with bone mineral density increase in response to daily teriparatide treatment in patients with osteoporosis

Bone ◽  
2014 ◽  
Vol 66 ◽  
pp. 26-30 ◽  
Author(s):  
Rui Niimi ◽  
Toshibumi Kono ◽  
Atsushi Nishihara ◽  
Masahiro Hasegawa ◽  
Akihiko Matsumine ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Bone Mineral ◽  
Density Increase ◽  
Mineral Density ◽  
Teriparatide Treatment ◽  
Bone Mineral Density Increase
Sign in / Sign up

Export Citation Format

Share Document